1-20 of 28
Michael A. Nauck
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes

Thomas Karagiannis, Apostolos Tsapas, Eleni Bekiari, Konstantinos A. Toulis, Michael A. Nauck
Journal: Diabetes Care
Diabetes Care 2024;47(2):184–192
https://doi.org/10.2337/dc23-0925
Published: 19 January 2024
View article titled, A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes
Open the PDF for A Methodological Framework for Meta-analysis and Clinical Interpretation of Subgroup Data: The Case of Major Adverse Cardiovascular Events With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes in another window
Journal Articles

Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes

Matthew C. Riddle, William T. Cefalu, Philip H. Evans, Hertzel C. Gerstein, Michael A. Nauck, William K. Oh, Amy E. Rothberg, Carel W. le Roux, Francesco Rubino, Philip Schauer, Roy Taylor, Douglas Twenefour
Journal: Diabetes Care
Diabetes Care 2021;44(10):2438–2444
https://doi.org/10.2337/dci21-0034
Published: 30 August 2021
View article titled, Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes
Open the PDF for Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes in another window
Journal Articles

Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes

Lea Aigner, Björn Becker, Sonja Gerken, Daniel R. Quast, Juris J. Meier, Michael A. Nauck
Journal: Diabetes Care
Diabetes Care 2021;44(2):479–488
https://doi.org/10.2337/dc20-1660
Published: 07 December 2020
View article titled, Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes
Open the PDF for Day-to-Day Variations in Fasting Plasma Glucose Do Not Influence Gastric Emptying in Subjects With Type 1 Diabetes in another window
Journal Articles

Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards

Michael A. Nauck, Juris J. Meier
Journal: Diabetes Care
Diabetes Care 2020;43(12):2906–2909
https://doi.org/10.2337/dci20-0062
Published: 08 October 2020
View article titled, Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards
Open the PDF for Reduced COVID-19 Mortality With Sitagliptin Treatment? Weighing the Dissemination of Potentially Lifesaving Findings Against the Assurance of High Scientific Standards in another window
Journal Articles

Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis

Jessica A. Huthmacher, Juris J. Meier, Michael A. Nauck
Journal: Diabetes Care
Diabetes Care 2020;43(9):2303–2312
https://doi.org/10.2337/dc20-0498
Published: 11 August 2020
View article titled, Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis
Open the PDF for Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis in another window
Journal Articles

Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes

Daniel R. Quast, Nina Schenker, Björn A. Menge, Michael A. Nauck, Christoph Kapitza, Juris J. Meier
Journal: Diabetes Care
Diabetes Care 2020;43(9):2137–2145
https://doi.org/10.2337/dc20-0720
Published: 09 July 2020
View article titled, Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes
Open the PDF for Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes in another window
Journal Articles

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial

John B. Buse, Stephen C. Bain, Johannes F.E. Mann, Michael A. Nauck, Steven E. Nissen, Stuart Pocock, Neil R. Poulter, Richard E. Pratley, Martin Linder, Tea Monk Fries, David D. Ørsted, Bernard Zinman
Journal: Diabetes Care
Diabetes Care 2020;43(7):1546–1552
https://doi.org/10.2337/dc19-2251
Published: 04 May 2020
View article titled, Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
Open the PDF for Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial in another window
Journal Articles

Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920

Michael A. Nauck, Eskil Kreiner, Søren Rasmussen, Hans A. Saevereid, John B. Buse
Journal: Diabetes Care
Diabetes Care 2020;43(2):e30–e31
https://doi.org/10.2337/dci19-0067
Published: 13 January 2020
View article titled, Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920
Open the PDF for Response to Comment on Nauck et al. Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial. Diabetes Care 2019;42:1912–1920 in another window
Journal Articles

Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial

Michael A. Nauck, Marie Louise Muus Ghorbani, Eskil Kreiner, Hans A. Saevereid, John B. Buse, the LEADER Publication Committee on behalf of the LEADER Trial Investigators
Journal: Diabetes Care
Diabetes Care 2019;42(10):1912–1920
https://doi.org/10.2337/dc19-0415
Published: 09 August 2019
View article titled, Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
Open the PDF for Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial

Michael A. Nauck, Thomas Jon Jensen, Carina Rosenkilde, Salvatore Calanna, John B. Buse, the LEADER Publication Committee on behalf of the LEADER Trial Investigators
Journal: Diabetes Care
Diabetes Care 2018;41(8):1663–1671
https://doi.org/10.2337/dc17-1825
Published: 13 June 2018
View article titled, Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial
Open the PDF for Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals

Lena Mumme, Thomas G.K. Breuer, Stephan Rohrer, Nina Schenker, Björn A. Menge, Jens J. Holst, Michael A. Nauck, Juris J. Meier
Journal: Diabetes Care
Diabetes Care 2017;40(10):1314–1322
https://doi.org/10.2337/dc17-0792
Published: 27 July 2017
View article titled, Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals
Open the PDF for Defects in α-Cell Function in Patients With Diabetes Due to Chronic Pancreatitis Compared With Patients With Type 2 Diabetes and Healthy Individuals in another window
Includes: Supplementary data
Journal Articles

Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial

William M. Steinberg, John B. Buse, Marie Louise Muus Ghorbani, David D. Ørsted, Michael A. Nauck, the LEADER Steering Committee, on behalf of the LEADER Trial Investigators
Journal: Diabetes Care
Diabetes Care 2017;40(7):966–972
https://doi.org/10.2337/dc16-2747
Published: 05 May 2017
View article titled, Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial
Open the PDF for Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide

Michael A. Nauck, Jean-Louis Frossard, Jamie S. Barkin, Greg Anglin, Ingrid E. Hensley, Kristine D. Harper, Zvonko Milicevic
Journal: Diabetes Care
Diabetes Care 2017;40(5):647–654
https://doi.org/10.2337/dc16-0984
Published: 10 March 2017
View article titled, Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide
Open the PDF for Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide in another window
Includes: Supplementary data
Journal Articles

A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

Michael A. Nauck, John R. Petrie, Giorgio Sesti, Edoardo Mannucci, Jean-Pierre Courrèges, Marie L. Lindegaard, Christine B. Jensen, Stephen L. Atkin
Journal: Diabetes Care
Diabetes Care 2016;39(2):231–241
https://doi.org/10.2337/dc15-0165
Published: 10 September 2015
View article titled, A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes
Open the PDF for A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance

Natalia Rudovich, Olga Pivovarova, Özlem Gögebakan, Andrea Sparwasser, Wolfram Doehner, Stefan D. Anker, Ayman M. Arafat, Andreas Bergmann, Michael A. Nauck, Andreas F.H. Pfeiffer
Journal: Diabetes Care
Diabetes Care 2015;38(1):e7–e8
https://doi.org/10.2337/dc14-1452
Published: 13 December 2014
View article titled, Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance
Open the PDF for Effect of Exogenous Intravenous Administrations of GLP-1 and/or GIP on Circulating Pro-Atrial Natriuretic Peptide in Subjects With Different Stages of Glucose Tolerance in another window
Journal Articles

Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes

Michaela Diamant, Michael A. Nauck, Rimma Shaginian, James K. Malone, Simon Cleall, Matthew Reaney, Danielle de Vries, Byron J. Hoogwerf, Leigh MacConell, Bruce H.R. Wolffenbuttel, for the 4B Study Group
Journal: Diabetes Care
Diabetes Care 2014;37(10):2763–2773
https://doi.org/10.2337/dc14-0876
Published: 10 September 2014
View article titled, Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
Open the PDF for Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: Reflections From a Diabetes Care Editors’ Expert Forum

William T. Cefalu, John B. Buse, Stefano Del Prato, Philip D. Home, Derek LeRoith, Michael A. Nauck, Itamar Raz, Julio Rosenstock, Matthew C. Riddle
Journal: Diabetes Care
Diabetes Care 2014;37(9):2647–2659
https://doi.org/10.2337/dc14-1395
Published: 07 August 2014
View article titled, Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: <subtitle>Reflections From a <em>Diabetes Care</em> Editors’ Expert Forum</subtitle>
Open the PDF for Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management: <subtitle>Reflections From a <em>Diabetes Care</em> Editors’ Expert Forum</subtitle> in another window
Journal Articles

Do GLP-1–Based Therapies Increase Cancer Risk?

Michael A. Nauck, MD, Nele Friedrich, PHD
Journal: Diabetes Care
Diabetes Care 2013;36(Supplement_2):S245–S252
https://doi.org/10.2337/dcS13-2004
Published: 17 July 2013
View article titled, Do GLP-1–Based Therapies Increase Cancer Risk?
Open the PDF for Do GLP-1–Based Therapies Increase Cancer Risk? in another window
Includes: Supplementary data
Journal Articles

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

Michael A. Nauck, MD,
Journal: Diabetes Care
Diabetes Care 2013;36(7):2126–2132
https://doi.org/10.2337/dc12-2504
Published: 12 June 2013
View article titled, A Critical Analysis of the Clinical Use of Incretin-Based Therapies: <subtitle>The benefits by far outweigh the potential risks</subtitle>
Open the PDF for A Critical Analysis of the Clinical Use of Incretin-Based Therapies: <subtitle>The benefits by far outweigh the potential risks</subtitle> in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial

Richard E. Pratley, MD, Michael A. Nauck, MD, Timothy Bailey, MD, Eduard Montanya, MD, Sebastiano Filetti, MD, Alan J. Garber, MD, Anne B. Thomsen, MD, Sabina Furber, MD, Melanie Davies, MD, for the 1860-LIRA-DPP-4 Study Group
Journal: Diabetes Care
Diabetes Care 2012;35(10):1986–1993
https://doi.org/10.2337/dc11-2113
Published: 11 September 2012
View article titled, Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: <subtitle>A randomized, open-label trial</subtitle>
Open the PDF for Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: <subtitle>A randomized, open-label trial</subtitle> in another window
Includes: Supplementary data